TY - JOUR T1 - Inherited Cancer Predisposition Syndromes in Greece JF - Anticancer Research JO - Anticancer Res SP - 1341 LP - 1347 VL - 28 IS - 2B AU - ANGELA APESSOS AU - EIRINI PAPADOPOULOU AU - IOULIA BELOGIANNI AU - SOTIRIS BARATSIS AU - JOHN K. TRIANTAFILLIDIS AU - PARIS KOSMIDIS AU - EIRINI KARYDAS AU - EVANGELOS BRIASOULIS AU - CHRISTOS PISIOTIS AU - KOSTAS PAPAZISIS AU - GEORGE NASIOULAS Y1 - 2008/03/01 UR - http://ar.iiarjournals.org/content/28/2B/1341.abstract N2 - Hereditary cancer syndromes comprise approximately 5-10% of diagnosed carcinomas. They are caused by mutations in specific genes. Carriers of mutations in these genes are at an increased risk of developing cancer at a young age. When there is a suspicion of a hereditary cancer predisposition syndrome a detailed family tree of the patient requesting screening is constructed. DNA is isolated from all available members of the family. Mutation detection is carried out on DNA from an affected family member. If a mutation is found the remaining family is screened. The genetic basis of a large number of inherited cancer predisposition syndromes is known. In this paper the focus is on mutations in genes responsible for colorectal cancer, meaning adenomatous polyposis coli (APC), which is involved in familial adenomatous polyposis and homo sapiens mutL homolog 1 (hMLH1) and homo sapiens mutS homolog 2 (hMSH2), involved in hereditary non-polyposis colorectal cancer. In addition, the genes responsible for inherited breast and/or ovarian cancer, breast cancer genes 1 and 2 (BRCA1 and BRCA2), and the rearranged during transfection proto-oncogene RET which is responsible for multiple endocrine neoplasia type 2 are discussed. In all cases emphasis is given to the data available on the Greek population. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -